BioMarin Pharmaceutical (NASDAQ: BMRN) and Ocera Therapeutics (NASDAQ:OCRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Volatility & Risk
BioMarin Pharmaceutical has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Ocera Therapeutics has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.
99.0% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 17.7% of Ocera Therapeutics shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 7.2% of Ocera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares BioMarin Pharmaceutical and Ocera Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioMarin Pharmaceutical||$1.12 billion||14.40||-$630.21 million||($0.83)||-110.36|
|Ocera Therapeutics||$610,000.00||77.79||-$26.89 million||($0.97)||-1.85|
Ocera Therapeutics has lower revenue, but higher earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Ocera Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and price targets for BioMarin Pharmaceutical and Ocera Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioMarin Pharmaceutical presently has a consensus target price of $114.00, indicating a potential upside of 24.45%. Ocera Therapeutics has a consensus target price of $4.19, indicating a potential upside of 133.94%. Given Ocera Therapeutics’ higher possible upside, analysts clearly believe Ocera Therapeutics is more favorable than BioMarin Pharmaceutical.
This table compares BioMarin Pharmaceutical and Ocera Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BioMarin Pharmaceutical beats Ocera Therapeutics on 8 of the 15 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
About Ocera Therapeutics
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.